Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
didanosine + stavudine
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Didanosine + stavudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs), used as antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) infection. Didanosine (ddI) and stavudine (d4T) both inhibit HIV reverse transcriptase by acting as chain terminators after incorporation into viral DNA, thereby preventing viral replication. This combination was historically used in both adults and children with HIV but is now largely discontinued due to significant toxicity concerns, including fatal lactic acidosis and pancreatitis, especially in pregnant women. The World Health Organization and other health authorities recommend against its use due to these risks[1][2][3][5][6]. The combination may still be referenced in older clinical studies or specific cases where alternative regimens are not available.
- Other names
- ddI + d4TVidex + Zerit
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on didanosine + stavudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on didanosine + stavudine.